Non-beta-lactam agents for definitive treatment of ampicillin-susceptible <i>Enterococcus</i> bacteremia: a single-center experience
NBL was used as definitive treatment in 27% of ASEB with good clinical outcomes. This real-life experience suggests NBL can be successfully used to treat ASEB based on clinical discretion.
Authors
- HeeEun Kang (ORCID: https://orcid.org/0009-0000-9794-9666)
- Isabella W. Martin (ORCID: https://orcid.org/0000-0001-7974-9767)
- Richard A. Zuckerman (ORCID: https://orcid.org/0000-0001-8883-9123)
- Justin Kim (ORCID: https://orcid.org/0000-0002-6544-6797)
- Asif Nawaz Khan
Institutions
- Dartmouth College (US)
- Dartmouth–Hitchcock Medical Center (US)
Publication Details
- Journal
- Antimicrobial Stewardship & Healthcare Epidemiology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1017/ash.2025.10078
- Primary Topic
- Antimicrobial Resistance in Staphylococcus
- Type
- article
- Field-Weighted Citation Impact
- 0.00